TNKS and pulmonary fibrosis: In addition, the potential therapeutic implications of tankyrase inhibitors are not limited to oncology but has also disseminated to multiple sclerosis (Fancy et al. 2011), pulmonary fibrosis (Ulsamer et al. 2012), and lipid disorder (Wang et al. 2020), highlighting the need for minimizing off-target effects and toxicity.